Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO -- First-dose reactions to IV ustekinumab (Stelara) may be related to IgE recognition of a carbohydrate ...
Ustekinumab-stba is approved for multiple conditions, showing comparable efficacy and safety to Stelara in clinical trials. The biosimilar will be available in subcutaneous and intravenous forms ...
Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...
Cigna's (NYSE:CI) pharmacy benefit manager, Evernorth Health Services, announced on Thursday plans to launch a biosimilar to ...
The FDA approved Steqeyma as the seventh Stelara biosimilar with an expected launch date of February 2025. Steqeyma’s indications match the reference product. The FDA has approved the Stelara ...
Symptoms of lupus include painful swollen joints, fever, rashes and chest pain ... This included an existing Janssen treatment, STELARA® (ustekinumab), which is approved for the treatment ...
The FDA has approved Celltrion’s Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for subcutaneous or intravenous use in adults and pediatric patients with plaque psoriasis and ...
Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved biosimilar in Europe, which is due to launch after the drug loses EU patent protection in July. The European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback